Dr. Thomas McNeil Schroeder, MD

Dr. Schroeder practices at University of New Mexico Hospital in Albuquerque, New Mexico, part of The University of New Mexico.

Dr. Schroeder's NPI, 1629280151, was assigned on May 4, 2007. Dr. Schroeder graduated from University of New Mexico School of Medicine in 2002. Dr. Schroeder holds New Mexico license MD2007-0200.

Dr. Schroeder's primary practice is University of New Mexico Hospital, at 2211 Lomas Boulevard NE, Albuquerque, NM 87106 in Bernalillo County. The practice phone is (505) 272-2111.

Dr. Schroeder's primary practice is University of New Mexico Hospital in Albuquerque, New Mexico, part of The University of New Mexico. The medical group on file is UNM Medical Group, Inc. Dmand AI also links Dr. Schroeder to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schroeder practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Schroeder's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Schroeder is licensed in New Mexico.

CMS data shows 1,332 Medicare services from Dr. Schroeder across 18 procedure codes in 2024, for 123 Medicare patients. Medicare paid $103,536 for them. Every service was in an office.

CMS counts 123 Medicare patients who saw Dr. Schroeder in 2024. The largest group is 65 to 74, with 59 patients. 75% of them have cancer, and 64% have high blood pressure. 17% are also on Medicaid. Their average risk score is 1.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Schroeder's median patient age at 73, with 34% women.

In 2024, Dr. Schroeder wrote 100 Medicare Part D claims for 36 patients. 87% of them were for generic drugs. CMS names the drug for 53 of them, across 2 drugs with 11 or more claims each, at $33,402 in total drug cost. In 2023, CMS named 51 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Schroeder for performance year 2024, reported as part of a group. Dr. Schroeder accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Schroeder as offering telehealth.

Dmand AI links 6 papers to Dr. Schroeder, published from 2011 to 2023. Dr. Schroeder's most frequent co-authors are Edward Bedrick, MD, Christian Andrew Bowers, MD and Steven C. Eberhardt, MD.

Dmand AI links Dr. Schroeder to 8 clinical trials, 3 of them phase 3 studies. 5 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis and Prostatic Neoplasms. NRG Oncology sponsors the most, 4.

CMS Open Payments shows 18 general payments to Dr. Schroeder from 8 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 96% of the total. Bioprotect Medical, Inc. paid the most, $325.

Dr. Schroeder graduated from University of New Mexico School of Medicine in 2002.